Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Cord Blood Cells in ALS: Replacement of Protection?

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease affecting motor neurons in the spinal cord, brainstem and cortex. We have previously shown that transplanting neuronal cells into the spinal cord delays the onset of motor symptoms in the G93A mouse model of ALS, but developing a potential treatment strategy around a committed neuronal cell or ...

    STTR Phase I 2004 Department of Health and Human Services
  2. Automated, portable, concurrent, WMD detection system

    SBC: Concurrent Analytical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is the development of a fully automated, wireless ethernet capable, near realtime, field deployable immunoassay-based analysis system for the concurrent, ultra low-level detection of biowarfare agents in air or water by using innovations in surface enhanced Raman scattering (SERS) and related supporting materials and hardware. A ...

    STTR Phase I 2004 Department of Health and Human Services
  3. Discovery of Anti-Bioweapon Agents in BAC Libraries

    SBC: EMETAGEN, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): Antibiotics are an essential component in bio-defense preparedness. Soil microorganisms were a major source of antibiotics during the 20th century, yet antibiotic discovery is now severely limited. A primary reason is that drug discovery from microorganisms has been confined to those microbes that can be recovered by laboratory cultivation, yielding high rates ...

    STTR Phase I 2004 Department of Health and Human Services
  4. Detecting Early Emerging Drug-Resistant HIV Populations

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment of human immunodeficiency virus type 1 (HIV) infection with antiretroviral agents invariably leads to selection and accumulation of drug-resistant mutants that arise due to the intrinsically low fidelity of HIV polymerase. Early detection of these growing variants may be clinically relevant. Before the level of clinical importance can be ascertained, ...

    STTR Phase I 2004 Department of Health and Human Services
  5. Pharmacophylogenomic Dates for the Master Catalog

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project will enhance the MASTERCATALOG, EraGen's product that combines an evolutionarily organized protein sequence database with tools to enable phylogenomics analysis. This will help maintain the commercial advantage of the MASTERCATALOG over public databases and tools, and help ensure that the MASTERCATALOG continues to enjoy its status as the "best in ...

    STTR Phase I 2004 Department of Health and Human Services
  6. Cytochlor/cytofluor: New Tumor Targeted Radiosensitizer

    SBC: HALOGENETICS            Topic: N/A

    DESCRIPTION (provided by applicant): Cytochlor Technology is about to enter a Phase I trial as a radiosensitizer of tumors of the oral cavity and oropharynx with NCI supervision. Our objective is to demonstrate Cytochlor's safety, selectivity and possible efficacy (although efficacy is not the goal of a Phase I trial). Our goal is to move Cytochlor Technology to a mutliinstitutional Phase II clini ...

    STTR Phase I 2004 Department of Health and Human Services
  7. Cytochlor/cytofluor: New Tumor Targeted Radiosensitizer

    SBC: HALOGENETICS            Topic: N/A

    DESCRIPTION (provided by applicant): Cytochlor Technology is about to enter a Phase I trial as a radiosensitizer of tumors of the oral cavity and oropharynx with NCI supervision. Our objective is to demonstrate Cytochlor's safety, selectivity and possible efficacy (although efficacy is not the goal of a Phase I trial). Our goal is to move Cytochlor Technology to a mutliinstitutional Phase II clini ...

    STTR Phase II 2004 Department of Health and Human Services
  8. Evolutionary Analysis of Protein using HyperChem

    SBC: HYPERCUBE            Topic: N/A

    DESCRIPTION (provided by applicant): At the end of Phase II, we will launch a new commercial product: HYPERPROTEIN. HYPERPROTEIN will be built on an existing software platform, HYPERCHEM, now in its commercial Version 7.5. HYPERCHEM is used in both education and industry to apply molecular modeling and computational chemistry to molecules. The feasibility of placing the HYPERPROTEIN product on th ...

    STTR Phase II 2004 Department of Health and Human Services
  9. POSITRON EMISSION TOMOGRAPHY GUIDED PROSTATE BIOPSY

    SBC: I.SOLUTIONS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer imaging with positron emission tomography (PET) has been facilitated by the recent development of the radioactive tracer fluorine-18 fluorocholine (F-18 FCH). Like other substrates for the enzyme choline kinase, F-18 FCH demonstrates increased accumulation in malignant cells. In addition to whole-body cancer staging, F-18 FCH PET may potentia ...

    STTR Phase I 2004 Department of Health and Human Services
  10. A Mechanistically Novel Antibiotic for Anthrax

    SBC: Nanopharma            Topic: N/A

    DESCRIPTION (provided by applicant): Anthrax is an infectious illness that has been known for many years, largely in rural settings, but since the terrorist attacks of 9-11, has recently emerged as a major national security concern. Bacillus anthracis, the causative agent of anthrax, exists naturally in various forms and is now considered a bioterrorism agent. There is fear that this microbe coul ...

    STTR Phase I 2004 Department of Health and Human Services
US Flag An Official Website of the United States Government